Ticker

Shares of MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) have earned an average rating of "Moderate Buy" from the five brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, one has issued a buy rating and two

LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament…

Shares of MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) have received an average recommendation of "Moderate Buy" from the five research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, one has given a buy recommendation and two

MediciNova (NASDAQ: MNOV - Get Free Report) and VivoSim Labs (NASDAQ: VIVS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Earnings and Valuation This table compares MediciNova and

LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D.